Advertisement
Screener

ANAVEX LIFE SCIENCES CORP. (AVXL) EBITDA

ANAVEX LIFE SCIENCES CORP. (AVXL) EBITDA

  • 2026-06-30: Basis Reported; EBITDA (m); Operating income $6.74M; Depreciation and amortization (m).
  • 2026-03-31: Basis Reported; EBITDA (m); Operating income -$6.48M; Depreciation and amortization (m).
  • 2025-12-31: Basis Reported; EBITDA (m); Operating income -$6.78M; Depreciation and amortization (m).
  • 2025-06-30: Basis Reported; EBITDA (m); Operating income -$14.46M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history
2014-09-30 to 2014-12-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported(m)$6.74M(m)(m)(m)(m)-$9.10M*(m)(m)$2.03M$0.00*
2026-03-31Reported(m)-$6.48M(m)(m)(m)(m)-$4.44M*(m)$4.19M$2.29M$0.00*
2025-12-31Reported(m)-$6.78M(m)(m)(m)(m)-$7.15M(m)$4.66M$2.13M$18.00K
2025-06-30Reported(m)-$14.46M(m)(m)(m)(m)-$12.46M*(m)$9.96M$4.50M(m)
2025-03-31Reported(m)-$12.51M(m)(m)(m)(m)-$5.86M*(m)$9.89M$2.62M(m)
2024-12-31Reported(m)-$13.59M(m)(m)(m)(m)-$12.12M(m)$10.45M$3.15M(m)
2024-06-30Reported(m)-$14.60M(m)(m)(m)(m)-$5.18M*(m)$11.81M(m)(m)
2024-03-31Reported(m)-$12.62M(m)(m)(m)(m)-$11.66M*(m)$9.73M(m)(m)
2023-12-31Reported(m)-$11.38M(m)(m)(m)(m)-$7.32M(m)$8.68M(m)(m)
2023-06-30Reported(m)-$13.53M(m)(m)(m)(m)-$7.65M*(m)$10.28M(m)(m)
2023-03-31Reported(m)-$14.19M(m)(m)(m)(m)-$8.49M*(m)$11.31M(m)(m)
2022-12-31Reported(m)-$15.38M(m)(m)(m)(m)-$5.79M(m)$12.07M(m)(m)
2022-06-30Reported(m)-$12.46M(m)(m)(m)(m)-$7.05M*(m)$9.27M(m)(m)
2022-03-31Reported(m)-$11.52M(m)(m)(m)(m)-$9.64M*(m)$8.60M(m)(m)
2021-12-31Reported(m)-$11.72M(m)(m)(m)(m)-$3.50M(m)$8.66M(m)(m)
2015-12-31Reported(m)(m)$249.00(m)(m)(m)(m)(m)$1.16M(m)$17.61K
2015-06-30Reported-$1.51M*-$1.51M$248.00*(m)(m)(m)-$1.43M*(m)$799.46K(m)(m)
2015-03-31Reported-$858.09K*-$858.34K$249.00*(m)(m)(m)-$670.28K*(m)$407.15K(m)(m)
2014-12-31Reported-$770,429.00(m)(m)(m)(m)(m)-$693.07K(m)$318.63K(m)(m)
2014-06-30Reported(m)-$998.83K(m)(m)(m)(m)-$960.00K*(m)$265.01K(m)(m)
2014-03-31Reported(m)-$1.02M(m)(m)(m)(m)-$347.53K*(m)$118.15K(m)(m)
2013-12-31Reported(m)-$309.61K(m)(m)(m)(m)-$434.99K(m)$5.18K(m)(m)
2013-06-30Reported(m)-$125.98K(m)(m)(m)(m)-$32.19K*(m)$39.02K(m)(m)
2013-03-31Reported(m)-$127.11K(m)(m)(m)(m)-$129.30K*(m)$560.00(m)(m)
2012-12-31Reported(m)-$415.87K(m)(m)(m)(m)-$131.57K(m)$127.00K(m)(m)
2012-06-30Reported(m)-$697.91K(m)(m)(m)(m)-$238.70K*(m)$393.96K(m)(m)
2012-03-31Reported(m)-$795.61K(m)(m)(m)(m)-$114.18K*(m)$429.61K(m)(m)
2011-12-31Reported(m)-$2.19M(m)(m)(m)(m)-$1.09M(m)$1.72M(m)(m)
2011-06-30Reported(m)-$1.64M(m)(m)(m)(m)-$1.21M*(m)$777.97K(m)(m)
2011-03-31Reported(m)-$1.95M(m)(m)(m)(m)-$588.94K*(m)$730.24K(m)(m)
2010-12-31Reported(m)-$1.37M(m)(m)(m)(m)-$1.08M(m)$497.29K(m)(m)
2010-06-30Reported(m)-$1.30M(m)(m)(m)(m)(m)(m)$613.16K(m)(m)

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-09-30Reported(m)-$51.41M(m)(m)(m)(m)-$39.04M(m)$37.59M$13.82M(m)
2024-09-30Reported(m)-$52.88M(m)(m)(m)(m)-$30.81M(m)$41.84M$11.04M(m)
2023-09-30Reported(m)-$55.76M(m)(m)(m)(m)-$27.79M(m)$43.72M$12.05M(m)
2022-09-30Reported(m)-$50.99M(m)(m)(m)(m)-$24.24M(m)$37.92M(m)(m)
2021-09-30Reported(m)-$42.00M(m)(m)(m)(m)-$30.38M(m)$32.98M(m)(m)
2020-09-30Reported(m)-$31.09M(m)(m)(m)(m)-$21.29M(m)$25.23M(m)(m)
2016-09-30Reported(m)(m)$1.25K(m)(m)(m)-$9.24M(m)$7.25M(m)(m)
2015-09-30Reported(m)(m)$995.00(m)(m)(m)-$4.23M(m)$2.27M(m)(m)
2014-09-30Reported-$2.97M(m)(m)(m)(m)$3.02K-$2.66M(m)$732.39K(m)-$1.40M
2013-09-30Reported(m)-$2.14M(m)(m)(m)(m)-$777.57K(m)$263.85K(m)(m)
2012-09-30Reported(m)-$4.32M(m)(m)(m)(m)-$1.69M(m)$2.65M(m)(m)
2011-09-30Reported(m)-$6.18M(m)(m)(m)(m)-$3.80M(m)$2.60M(m)(m)
2010-09-30Reported(m)-$5.65M(m)(m)(m)(m)-$4.59M(m)$2.73M(m)(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87
Alector, Inc. (ALEC)United States$0.213B-1.90
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
Protara Therapeutics, Inc. (TARA)United States$0.198B-3.22
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95